Background Patients who have had an acute coronary syndrome are at high risk for recurrent
ischemic cardiovascular events. We sought to determine whether alirocumab, a human …

Background Management of acute coronary syndromes (ACS) should be guided by an
estimate of patient risk. Objective To develop a simple model to assess the risk for in-hospital …

Background Among patients with stable coronary disease and moderate or severe ischemia,
whether clinical outcomes are better in those who receive an invasive intervention plus …

ContextAccurate estimation of risk for untoward outcomes after patients have been hospitalized
for an acute coronary syndrome (ACS) may help clinicians guide the type and intensity of …

Objective To develop a clinical risk prediction tool for estimating the cumulative six month risk
of death and death or myocardial infarction to facilitate triage and management of patients …

Background The effect of intensified platelet inhibition for patients with unstable angina or
myocardial infarction without ST-segment elevation who do not undergo revascularization has …

ContextRandomized trials provide robust evidence for the impact of pharmacological and
interventional treatments in patients with ST-segment elevation and non–ST-segment …

Background Appropriate antithrombotic regimens for patients with atrial fibrillation who have
an acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) …

Aims Despite advances in the treatment of acute coronary syndromes based on randomized
trial data and published guidelines, the extent to which such treatments are applied in …

Background— Patients with diabetes mellitus (DM) are at high risk for recurrent cardiovascular
events after acute coronary syndromes, in part because of increased platelet reactivity. …